Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Posts Q3 Revenue Rise

SAN FRANCISCO, Nov. 13 - Exelixis on Tuesday posted third-quarter revenues of $11.9 million versus $6.1 for the same quarter a year ago, the company announced.


The South San Francisco-based company attributed the revenue rise to new collaborations with Bristol-Myers Squibb and Protein Design Labs.


Exelixis reported a net loss of $13.4 million, or 28 cents per share for the third quarter of 2001, compared to a net loss of $5.5 million, or 13 cents per share for the third quarter of 2000.


General and administrative expenses for the period increased to $4.8 million from $2.6 million for the year-ago period. Research and development rose to $21.3 million from $11.1 million for the third quarter of 2000.


"The third quarter was highly productive for Exelixis, both in establishing key strategic partnerships with leading companies such as Bristol-Myers Squibb and Elan and in moving our internal programs forward aggressively," George Scangos, CEO of Exelixis, said in a statement. "We remain on track to announce our first lead compound by year end."


The company reported $132.3 million in cash, cash equivalents and short-term investments as of September 30, 2001.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.